Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NUVB vs STOK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STOK Captures Overall Composite Edge (55.9 HOLD vs 61.0 BUY), While NUVB Leads 4–1 on Growth & Valuation Pillars

STOK Overall Winner 6-Pillar Tally: NUVB 4 – 1 STOK (1 Tie) Matrix Metrics: NUVB 4 – 4 STOK

As of Nov 20, 2026, Stoke Therapeutics, Inc. (STOK) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (55.9/100 HOLD vs. 61.0/100 BUY) after splitting the core matrix 4–4 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus STOK at $26.81 (N/M Forward P/E, -913.2% operating margin).

  • Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. STOK 55.9/100 HOLD), STOK captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-913.2% vs. -61.2% operating margin) and revenue trajectory (+5.9% vs. +242.6% YoY).
  • Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NUVB vs STOK
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87
STOK NASDAQ Head-to-Head Winner
Stoke Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$26.81
-0.45% 1D
Market Cap $1.8B
TTM Revenue $28M
Forward P/E N/M
Beta / 30D Vol 0.83β · 38% Vol
Unified Composite Score
55.9 / 100 HOLD
Tech 43.0 Fund 56.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.1 · SMA20: $26.66 · SMA50: $26.16

6-Pillar Scorecard Institutional Category Breakdown (NUVB 4 – 1 STOK)

Columns: Metric · NUVB · STOK
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 7.4x 58.7x
2. Growth & Scale NUVB
Revenue Growth (YoY) +242.6% +5.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $202M $28M
Market Cap $1.3B $1.8B
3. Profitability & Quality NUVB
Gross Margin 85.8% 100.0%
Operating Margin -61.2% -913.2%
Net Profit Margin -67.4% 0.0%
Return on Equity (ROE) -49.1% -73.6%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$108M -$216M
Cash Flow Margin -53.6% N/A
Net Cash / Leverage $146M Net Debt (1.32x D/E) $106M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STOK
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 65.2% (26th %ile) 63.5% (8th %ile)
Put/Call OI Skew 0.24x (Call-Skewed) 0.27x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NUVB (4) vs STOK (4)
Institutional Metric NUVB STOK Criterion Row Edge
Market Capitalization
Scale
$1.3B $1.8B Larger Scale STOK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+242.6% +5.9% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-61.2% -913.2% Higher Margin NUVB
Net Profit Margin
Profitability
-67.4% 0.0% Higher Margin STOK
Return on Equity (ROE)
Capital Efficiency
-49.1% -73.6% Higher ROE NUVB
52-Week Range Position
Momentum
2% ($4–$10) 26% ($22–$40) Stronger Trend STOK
Beta / 30D Volatility
Risk Regime
1.52β · 55% Vol 0.83β · 38% Vol Lower Realized Risk STOK
Unified Institutional Score
Composite Signal
61.0 / 100 (BUY) 55.9 / 100 (HOLD) Higher Composite NUVB
Trailing 12M Revenue (USD)
Operating Scale
$202M $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.8% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.4x EV/Rev N/M PEG · 58.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$108M ($146M Net Debt (1.32x D/E)) -$216M ($106M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STOK +23.47 pp
NUVB: -19.15% · STOK: +4.32%
3M Horizon STOK +26.74 pp
NUVB: -43.79% · STOK: -17.05%
6M Horizon STOK +10.87 pp
NUVB: -19.49% · STOK: -8.62%
1Y Horizon STOK +40.99 pp
NUVB: -46.85% · STOK: -5.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NUVB Revenue STOK Revenue NUVB Op. Margin STOK Op. Margin Margin Leader
FY2022 N/A $10M N/A -841.2% STOK
FY2023 N/A $10M N/A -1307.2% STOK
FY2024 $10M $40M -7527.3% -277.3% STOK
FY2025 $60M $180M -338.7% -11.2% STOK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STOK SURGE
7d in phase · OBV NEUTRAL
Current IV 63.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.27x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact STOK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STOK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.8B market capitalization and -913.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NUVB vs STOK Key Questions & Quantitative Answers

As of Nov 20, 2026, Stoke Therapeutics, Inc. (STOK) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (55.9/100 HOLD vs. 61.0/100 BUY) after splitting the core matrix 4–4 (led by Options & Positioning), while NUVB wins 4–1 across the 6-pillar growth and valuation breakdown. NUVB trades at $3.80 (N/M Forward P/E, -61.2% operating margin) versus STOK at $26.81 (N/M Forward P/E, -913.2% operating margin). Composite vs. Pillar Nuance: While NUVB currently prints a higher short-term Unified Composite Score (61.0/100 BUY vs. STOK 55.9/100 HOLD), STOK captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-913.2% vs. -61.2% operating margin) and revenue trajectory (+5.9% vs. +242.6% YoY). Technical & Structure Timing Caution: NUVB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile STOK trades in a Neutral technical trend (SURGE options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: NUVB posts +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin), compared with STOK at +5.9% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (100.0% gross margin, -913.2% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), NUVB cumulative revenue shifted +500.0% while STOK shifted +1700.0%. In operating R&D and SG&A reinvestment, NUVB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for STOK.

NUVB screens cheaper on headline valuation multiples. NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin), whereas STOK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 58.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NUVB (-49.1% ROE) versus STOK (-73.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk). By comparison, STOK carries 63.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.27x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.83β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.